Subtractive Genomic Analysis for Identification of Novel Drug Targets and Vaccine Candidates against Bartonella bacilliformis subsp. Ver097

Bartonella bacilliformis is the causative agent of Carrión’s disease, one of the truly neglected tropical diseases found in Peru, Colombia and Ecuador. Recent evidence predicts that Bartonella bacilliformis subsp. ver097 can emerge as an antibacterial resistant strain and hence identification of novel drug targets is a crying need. Subtractive genome analysis of B. bacilliformis subsp. ver097 was successfully done in order to address the challenges. Various computational tools and online based servers were used to screen out human homologous proteins of pathogen and proteins involved in common metabolic pathways of host and pathogen. Only 7 proteins involved in pathogen specific pathways were further analyzed to identify membrane proteins. ‘Flagellar biosynthesis protein FlhA’ and ‘ABC transporter permease’ were found to be novel as targets according to DrugBank database. To avoid side effects in human while administering drugs, human ‘anti-targets’ analysis was performed to confirm non-homology of selected novel drug targets. Both predicted proteins also showed probability of antigenicity prediction through VaxiJen, however, ‘Flagellar biosynthesis protein FlhA’ showed broad spectrum conservancy with Bartonella strains. Therefore, Flagellar biosynthesis protein FlhAcould facilitate the development of novel drugs and therapeutic compounds along with vaccines for efficient treatment of infections caused by Bartonella bacilliformis subsp. ver097.

[1]  D. Carr,et al.  Bartonellosis , 1944 .

[2]  L. Parish.  Clinics in dermatology , 1983 .

[3]  W. Schofield.  Overview and update. , 1987 .

[4]  E. Wright,et al.  Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  H. Fenner.  Evaluation of the efficacy and safety of NSAIDs. A new methodological approach. , 1989, Scandinavian journal of rheumatology. Supplement.

[6]  P. Kelley,et al.  An epidemic of Oroya fever in the Peruvian Andes. , 1990, The American journal of tropical medicine and hygiene.

[7]  B. Alexander,et al.  A review of bartonellosis in Ecuador and Colombia. , 1995, The American journal of tropical medicine and hygiene.

[8]  L. Lasagna,et al.  Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective , 1995, Clinical pharmacology and therapeutics.

[9]  G. Ihler.  Bartonella bacilliformis: dangerous pathogen slowly emerging from deep background. , 1996, FEMS microbiology letters.

[10]  Akiyasu C. Yoshizawa,et al.  KAAS: an automatic genome annotation and pathway reconstruction server , 2007, Environmental health perspectives.

[11]  D. Raoult,et al.  In Vitro Susceptibilities of Four Bartonella bacilliformis Strains to 30 Antibiotic Compounds , 1999, Antimicrobial Agents and Chemotherapy.

[12]  S. Lukyanov,et al.  Identification and localization of differences between Escherichia coli and Salmonella typhimurium genomes by suppressive subtractive hybridization , 1999, Molecular and General Genetics MGG.

[13]  P. Moses,et al.  Severe hepatotoxicity associated with bromfenac sodium , 1999, American Journal of Gastroenterology.

[14]  J. Mekalanos,et al.  TnAraOut, A transposon-based approach to identify and characterize essential bacterial genes , 2000, Nature Biotechnology.

[15]  B. Wolf,et al.  Amino acid homologies between human biotinidase and bacterial aliphatic amidases: putative identification of the active site of biotinidase. , 2000, Molecular genetics and metabolism.

[16]  R. Rappuoli.  Reverse vaccinology : Genomics , 2000 .

[17]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[18]  E. Gotuzzo,et al.  Bartonellosis. New and old. , 2000, Infectious disease clinics of North America.

[19]  R. Rappuoli,et al.  Reverse vaccinology: a genome-based approach for vaccine development , 2002, Expert opinion on biological therapy.

[20]  K. Hornbuckle,et al.  Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .

[21]  R. Rappuoli,et al.  Reverse vaccinology, a genome-based approach to vaccine development. , 2001 .

[22]  C. Maguiña,et al.  Bartonelosis (Carrion's Disease) in the pediatric population of Peru: an overview and update. , 2004, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[23]  C. Maguiña,et al.  Report of an unusual case of persistent bacteremia by Bartonella bacilliformis in a splenectomized patient. , 2004, The American journal of tropical medicine and hygiene.

[24]  Hong-Yu Ou,et al.  EG: a database of essential genes , 2004, Nucleic Acids Res..

[25]  S. Gordon,et al.  The Burden of Acute Nonfulminant Drug-induced Hepatitis in a United States Tertiary Referral Center , 2005, Journal of clinical gastroenterology.

[26]  Jenn-Kang Hwang,et al.  Prediction of protein subcellular localization , 2006, Proteins.

[27]  Yuki Moriya,et al.  KAAS: an automatic genome annotation and pathway reconstruction server , 2007, Nucleic Acids Res..

[28]  D. Flower,et al.  Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. , 2007, Vaccine.

[29]  Brian R. King,et al.  ngLOC: an n-gram-based Bayesian method for estimating the subcellular proteomes of eukaryotes , 2007, Genome biology.

[30]  D. Raoult,et al.  Molecular mechanisms of resistance to antibiotics in Bartonella bacilliformis. , 2007, The Journal of antimicrobial chemotherapy.

[31]  I. Margarit,et al.  Surfome Analysis as a Fast Track to Vaccine Discovery , 2009, Molecular & Cellular Proteomics.

[32]  R. Aggarwal,et al.  Subtractive Genomics Approach for in Silico Identification and Characterization of Novel Drug Targets in Neisseria Meningitides Serogroup B , 2009 .

[33]  Martin Ester,et al.  PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes , 2010, Bioinform..

[34]  Ying Gao,et al.  Bioinformatics Applications Note Sequence Analysis Cd-hit Suite: a Web Server for Clustering and Comparing Biological Sequences , 2022 .

[35]  Sethi Pk,et al.  Definition of Potential Targets in Mycoplasma Pneumoniae Through Subtractive Genome Analysis , 2010 .

[36]  C. M. Vargas,et al.  Actualización de la enfermedad de Carrión. , 2012 .

[37]  B. Shanmugham,et al.  Identification and Characterization of Potential Therapeutic Candidates in Emerging Human Pathogen Mycobacterium abscessus: A Novel Hierarchical In Silico Approach , 2013, PloS one.

[38]  J. Bartlett,et al.  Seven ways to preserve the miracle of antibiotics. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  A. Chakraborty,et al.  Identification of potential targets in Staphylococcus aureus N315 using computer aided protein data analysis , 2013, Bioinformation.

[40]  J. Suh,et al.  Putative drug and vaccine target protein identification using comparative genomic analysis of KEGG annotated metabolic pathways of Mycoplasma hyopneumoniae. , 2013, Genomics.

[41]  O. Bagasra,et al.  Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. , 2014, Journal of infection in developing countries.

[42]  D. Dominey-Howes,et al.  The Antimicrobial Resistance Crisis: Causes, Consequences, and Management , 2014, Front. Public Health.

[43]  Kiran Saeed,et al.  Identification and characterization of potential drug targets by subtractive genome analyses of methicillin resistant Staphylococcus aureus , 2014, Comput. Biol. Chem..

[44]  Yan Lin,et al.  DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements , 2013, Nucleic Acids Res..

[45]  Francesco Paduano,et al.  Extended LineSets: a visualization technique for the interactive inspection of biological pathways , 2015, BMC Proceedings.

[46]  M. J. Pons,et al.  Antibiotic resistance in Bartonella bacilliformis clinical isolates from an endemic area of Peru. , 2015, Journal of global antimicrobial resistance.

[47]  Md. Muzahidul Islam,et al.  Advances and Applications in Bioinformatics and Chemistry Dovepress Identification of Potential Drug Targets by Subtractive Genome Analysis of Escherichia Coli O157:h7: an in Silico Approach , 2022 .

[48]  J. Ruiz,et al.  Proteins of Bartonella bacilliformis: Candidates for Vaccine Development , 2015, International journal of peptides.

[49]  Sandip Paul,et al.  Mutation-Driven Divergence and Convergence Indicate Adaptive Evolution of the Intracellular Human-Restricted Pathogen, Bartonella bacilliformis , 2016, PLoS neglected tropical diseases.

[50]  C. Gomes,et al.  Development and characterisation of highly antibiotic resistant Bartonella bacilliformis mutants , 2016, Scientific Reports.

[51]  M. Kamruzzaman,et al.  Application of the Subtractive Genomics and Molecular Docking Analysis for the Identification of Novel Putative Drug Targets against Salmonella enterica subsp. enterica serovar Poona , 2017, BioMed research international.

[52]  PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis , 2017, Annals of Clinical Microbiology and Antimicrobials.

[53]  Reaz Uddin,et al.  Prioritization of potential drug targets against P. aeruginosa by core proteomic analysis using computational subtractive genomics and Protein-Protein interaction network , 2018, Comput. Biol. Chem..

[54]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[55]  M. J. Pons,et al.  Revisiting Bartonella bacilliformis MLST. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[56]  M. Hasan,et al.  Reverse vaccinology approach to design a novel multi-epitope subunit vaccine against avian influenza A (H7N9) virus , 2018, bioRxiv.

[57]  M. Hasan,et al.  Reverse vaccinology approach to design a novel multi-epitope subunit vaccine against avian influenza A (H7N9) virus , 2018, bioRxiv.

[58]  M. Hasan,et al.  Vaccinomics strategy for developing a unique multi-epitope monovalent vaccine against Marburg marburgvirus , 2018, bioRxiv.

[59]  M. Hasan,et al.  Immunoinformatics approaches for designing a novel multi epitope peptide vaccine against human norovirus (Norwalk virus). , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.